Skip to main content

Advertisement

SpringerLink
Log in

Lipidsenkende Therapie zur Sekundärprävention der peripheren arteriellen Verschlusskrankheit

Einfluss der neuen Leitlinien der Europäischen Gesellschaft für Kardiologie/Europäischen Atherosklerose Gesellschaft (ESC/EAS)

Lipid-lowering treatment for secondary prevention of peripheral arterial occlusive disease

Influence of the new guidelines of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS)

  • Leitthema
  • Published:
Gefässchirurgie Aims and scope Submit manuscript

Zusammenfassung

Fettstoffwechselstörungen gehören neben Bluthochdruck, Rauchen und Diabetes mellitus zu den primären Risikofaktoren, die die Entstehung und den Verlauf der peripheren arteriellen Verschlusskrankheit (PAVK) maßgeblich beeinflussen. Die zentrale Bedeutung der Behandlung der Fettstoffwechselstörungen, insbesondere die Senkung des LDL-Cholesterins (LDL-C), wird in den aktuellen Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC)/Europäischen Atherosklerose Gesellschaft (EAS) noch einmal besonders hervorgehoben.

Abstract

In addition to arterial hypertension, smoking and diabetes mellitus, dyslipidemia is one of the primary risk factors that significantly influence the development and progress of peripheral arterial occlusive disease (PAOD). The treatment of dyslipidemia is of crucial importance, especially for lowering of low-density lipoprotein cholesterol (LDL-C) levels, which has been accentuated once again in the current guidelines of the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 1

Literatur

  1. Aboyans V, Ricco J‑B, Bartelink M‑LEL et al (2018) 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39:763–816

    Article  Google Scholar 

  2. Armstrong EJ, Chen DC, Westin GG et al (2014) Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. JAHA 3:e697

    Article  Google Scholar 

  3. Arya S, Khakharia A, Binney ZO et al (2018) Association of Statin dose with amputation and survival in patients with peripheral artery disease. Circulation 137:1435–1446

    Article  CAS  Google Scholar 

  4. Bhatt DL, Eagle KA, Ohman EM et al (2010) Comparative determinants of 4‑year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350–1357

    Article  CAS  Google Scholar 

  5. Bhatt DL, Steg PG, Miller M et al (2019) Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11–22

    Article  CAS  Google Scholar 

  6. Bonaca MP, Nault P, Giugliano RP et al (2017) Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 137:338–350. https://doi.org/10.1161/CIRCULATIONAHA.117.032235

  7. Cacoub PP, Abola MTB, Baumgartner I et al (2009) Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis 204:e86–e92

    Article  CAS  Google Scholar 

  8. Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058

    Article  Google Scholar 

  9. Cholesterol Treatment Trialists C (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 376:1670–1681

    Article  Google Scholar 

  10. Criqui MH, Langer RD, Fronek A et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381–386

    Article  CAS  Google Scholar 

  11. Diaz MN, Frei B, Vita JA et al (1997) Antioxidants and atherosclerotic heart disease. N Engl J Med 337:408–416

    Article  CAS  Google Scholar 

  12. Dopheide JF, Papac L, Schindewolf M et al (2018) Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. J Clin Lipidol 12:711–717

    Article  Google Scholar 

  13. Dopheide JF, Veit J, Ramadani H et al (2019) Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvz081

  14. Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459–2472

    Article  CAS  Google Scholar 

  15. Gaudet D, Kereiakes DJ, Mckenney JM et al (2014) Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 114:711–715

    Article  CAS  Google Scholar 

  16. Jukema JW, Szarek M, Zijlstra LE et al (2019) Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol 74:1167–1176

    Article  CAS  Google Scholar 

  17. Kato ET, Cannon CP, Blazing MA et al (2017) Efficacy and safety of adding ezetimibe to Statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). J Am Heart Assoc 6(11):pii:e006901. https://doi.org/10.1161/JAHA.117.006901

  18. Mach F, Baigent C, Catapano AL et al (2019) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455

  19. Raal FJ, Giugliano RP, Sabatine MS et al (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63:1278–1288

    Article  CAS  Google Scholar 

  20. Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 295:369–377

    Article  CAS  Google Scholar 

  21. Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722

    Article  CAS  Google Scholar 

  22. Steinbrecher UP, Parthasarathy S, Leake DS et al (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci 81:3883–3887

    Article  CAS  Google Scholar 

  23. Szarek M, White HD, Schwartz GG et al (2019) Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 73:387–396

    Article  CAS  Google Scholar 

  24. Vonbank A, Drexel H, Agewall S et al (2018) Reasons for disparity in Statin adherence rates between clinical trials and real world observations. A review. Eur Heart J Cardiovasc Pharmacother 4(4):230–236. https://doi.org/10.1093/ehjcvp/pvy028

  25. Williams KJ, Tabas I (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551–561

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schweizer Herz- und Gefässzentrum, Inselspital Bern, Freiburgstr. 8, 3010, Bern, Schweiz

    J. F. Dopheide

  2. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) A-Feldkirch, Private Universität im Fürstentum Liechtenstein, Drexel University College of Medicine, Philadelphia, PA, USA

    H. Drexel

Authors
  1. J. F. Dopheide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Drexel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. F. Dopheide.

Ethics declarations

Interessenkonflikt

J. F. Dopheide gibt an, für AMGEN Switzerland Ag in beratender Funktion tätig zu sein. H. Drexel gibt an, in beratender Funktion für folgende Firmen tätig gewesen zu sein: NovoNordisk, Merck, MSD, Pfizer, Sanofi-Aventis, AstraZeneca, Bayer, Takeda, Daiichi-Sankyo, Novartis, Amgen, Boehringer Ingelheim, BMS, Abbott, Janssen-Cilag, Genericon.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dopheide, J.F., Drexel, H. Lipidsenkende Therapie zur Sekundärprävention der peripheren arteriellen Verschlusskrankheit. Gefässchirurgie 25, 160–165 (2020). https://doi.org/10.1007/s00772-020-00629-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00772-020-00629-0

Schlüsselwörter

Keywords

Search

Navigation